| Study | Drug A | Drug B | Control | Dose | Frequency | Type of inhaler | Notes |
| Avital 1992 | Salbutamol | Ipratropium | Placebo | Salbutamol: 2.5 mg Ipratropium: 0.25 mg | Single dose | | Cross‐over trial. Methacholine challenge doubling concentrations of inhaled methacholine 5 minutes apart with FEV1 |
| Dodd 2005 | Salbutamol | | Placebo | Salbutamol: 600 mcg Ipratropium: 0.25 mg | Single dose | | Cross‐over trial. |
| Duncan 1982 | Salbutamol | | Saline | Salbutamol: 0.5 mg | prior to physiotherapy (3 days) | | Cross‐over trial. |
| Eggleston 1991 | Albuterol | | Placebo | Albuterol: 90 mcg | 4x daily (4 weeks) | MDI | Cross‐over trial. Participants subdivided into responders or non‐responders by methacholine challenge |
| Hordvik 1996 | Albuterol | | Placebo | 5mg | 3x prior to CPT (1 day) | | Cross‐over trial. |
| Hordvik 1999 | Albuterol | Salmeterol | Placebo | Albuterol: 180 mcg
Salmeterol: 42 mcg | Albuterol: 4x prior to CPT (1 day)
Salmeterol: 2x prior to 1st and 4th CPT (1 day)
Placebo: 4x prior to CPT (1 day) | MDI | 3‐way cross‐over trial |
| Hordvik 2002 | Albuterol & placebo | Salmeterol & placebo | | Albuterol: 2.5 mg Salmeterol: 100 mcg | both given 2x daily (Short‐term arm 4 weeks; long‐term arm 26 weeks). | | Cross‐over trial. Abuterol nebulised and placebo discus; Salmeterol discus and placebo nebulised. |
| Konig 1998 | Albuterol | | Placebo | Albuterol: 180 mcg | 2x daily (6 months) | MDI | Cross‐over trial. |
| Pitcher 1982 | Salbutamol | Ipratropium | Saline | Salbutamol: 5 ‐ 10 mg Ipratropium: 250 ‐ 500 mcg | Single dose (2 ‐ 6 months) | | Cross‐over trial. |
| Salvatore 2002 | Salmeterol | | Placebo | Salmeterol: 84 mcg | 1x daily (45 mins before bed), repeat 48 hours later | | Cross‐over trial. Day 1: albuterol challenge (200 mcg via MDI) to determine responders |
| Sanchez 1992 | Albuterol | Ipratropium | Placebo | Albuterol: 5 mg
Ipratropium: 2.5 mg | Single dose of each (3 days) | | Cross‐over trial. |
| Sanchez 1993 | Salbutamol | Ipratropium | | Salbutamol: 200 ‐ 400 mcg Ipratropium: 80 mcg | Single dose of each sequence, dose of each drug separated by 45 mins (2 days). | MDI & aerochamber | Cross‐over trial. Sequence A: salbutamol 200 mcg, salbutamol 400 mcg and ipratropium 80 mcg; or Sequence B: ipratropium 80 mcg, salbutamol 200 mcg, salbutamol 400 mcg |
| Serisier 2007 | Salbutamol | | Placebo | Salbutamol: 600 mcg | Single dose prior to cycle ergometry. | MDI with spacer | Cross‐over trial. Histamine challenge test was performed to assess bronchial hyper‐reactivity but no information given. |
| Sheehan 2003 | Albuterol | | Placebo | Albuterol: 180 mcg | Albuterol: 2 minute intervals until heat rate increased by 10% (maximum of 8 puffs);
Placebo: 2 puffs at 2 minute intervals (maximum 6 puffs). | MDI with spacer (Aerochamber MV) | Parallel trial. |
| Turchetta 1996 | Salbutamol | Salmeterol | | Salbutamol: 2 puffs Salmeterol: 2 puffs | Salbutamol: 3x daily (30 days)
Salmeterol: 2x daily (30 days) | | Cross‐over trial. No washout period. |
| Turchetta 1998 | Salmeterol | | Placebo | 2 puffs | 2x daily (1 month) | MDI with spacer | Parallel trial. |
| Wiebicke 1990 | Ipratropium bromide solution | | 0.9 % hypertonic saline solution | Ipratropium bromide: 2 ml Hypertonic saline: 2 ml | Single dose of each (over 2 weeks) | | Cross‐over trial. Ipratropium bromide solution (Atrovent® = 250 ?g in 1 ml hypertonic saline solution). |
| Ziebach 2001 | Salbutamol | Ipratropium | Placebo | Salbutamol: 5 mg Ipratropium: 0.25 mg | Single dose of each (4 days) | | Cross‐over trial. Randomised to nebulised placebo, salbutamol, ipratropium or combination. |
